President and CEO Doug Love outlined a series of anticipated clinical and regulatory milestones during the 25th Annual ...

Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...

First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving ...

C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...

ETHNOPHARMACOLOGICAL RELEVANCE: Esculetin is a bioactive compound of medicinal herb Hydrangea paniculata, and has showed anti-oxidation and anti-inflammation bioactivities. Renal local oxidative ...

Immunoglobulin A (IgA) nephropathy is an autoimmune disease characterized by the deposition of circulating IgA-containing ...

Discover large garden ideas to give your outdoor space more beauty and functionality. Think: pathways, trellises, raised beds ...

Omeros Corporation (NASDAQ:OMER) Q4 2025 Earnings Call Transcript April 1, 2026 Operator: Good afternoon, and welcome to today’s earnings call for Omeros Corporation. [Operator Instructions] Please be ...